Statins and the Risk of Prostate Cancer or Benign Prostatic Hyperplasia: Biological Plausibility

References 

1. Murtola TJ, Tammela TL, Maattanen L, et al. Prostate cancer and PSA among statin users in the Finnish Prostate Cancer Screening Trial. Int J Cancer. January 13, 2010;Epub ahead of print
2. Mondul AM, Selvin E, De Marzo AM, et al. Statin drugs, serum cholesterol, and prostate-specific antigen in the National Health and Nutrition Examination Survey 2001–2004. Cancer Causes Control. 2010;12:671
3. Schenk JM, Kristal AR, Neuhouser ML, et al. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. Am J Epidemiol. 2010;171:571
   • CrossRef
4. Zheng X, Cui XX, Gao Z, et al. Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence. Cancer Prev Res (Phila Pa). 2010;3:114
   • CrossRef
5. Banez LL, Klink JC, Jayachandran J, et al. Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy. Cancer Epidemiol Biomarkers Prev. 2010;19:722
   • CrossRef
6. Zhuang L, Kim J, Adam RM, et al. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest. 2005;115:959
   • MEDLINE
   • CrossRef
7. Parikh A, Childress C, Deitrick K, et al. Statin-induced autophagy by inhibition of geranylgeranyl biosynthesis in prostate cancer PC3 cells. Prostate. 2010;Epub ahead of print
8. Sekine Y, Furuya Y, Nichii M, et al. Simvastatin inhibits the proliferation of human prostate cancer pc-3 cells via down-regulation of the insulin-like growth factor 1 receptor. Biochem Biophys Res Commun. 2008;372:356
   • CrossRef